



# **NEWSLETTER JUNE 2024**

### **BOARD OF DIRECTORS**

Ramandeep Arora Amita Mahajan Revathy Raj Gauri Kapoor

### **SUBCOMMITTEE CHAIRS**

V Radhakrishnan **ALL** AML & Ch Myel Smita Kayal HL Payal Malhotra NHL Nirmalaya Moulik Histio Ramya Uppuluri CNS Vikramjit Kanwar **NBL** Yamini Krishnan Retino Amita Mahajan Renal Shalini Mishra Liver **Vimal Kumar PNET** Vasudev Bhat Osteo **Akshay Tiwari STS** Reghu KS **GCT & Rare** Sonali Mohapatra Ponni Sivaprakasan **HSCT** Acc to Care Shruti Kakkar **Supportive** Gargi Das Ramandeep Arora **Epidemiology** Sur & LE Rachna Seth **Palliative Veronique Dinand Can Genetics Badira CP** Cell & Gene **Gaurav Narula** Hbpathy/RBC **Bhavna Dhingra** 

### **TABLE OF CONTENTS**

- **Membership Update** 1.
- 2. **Subcommittee Update**
- 3. **Our Staff**
- **Staff Training** 4.
- 5. **Technical Advisors**
- 6. **Study Portfolio** 
  - a. Overview
  - b. Recruitment Complete
  - c. Recruitment Ongoing
  - d. Full Registration
  - e. Provisional Registration



Plat & Coag

**BM Failure** 







V Bharadwaj

**Mukul Agarwal** 



We are proud to announce that we have received the 12A and 80G certification. This achievement affirms our dedication transparency and excellence, and it allows us to amplify our impact through increased financial support and donor confidence.



### **MEMBERSHIP UPDATE**

We are excited to announce that we have achieved a significant member / institutions! milestone reaching 50 accomplishment highlights our expanding influence and the dedication of our research community in pursuing our common objectives. We sincerely thank each member for their ongoing support and collaboration, which has been crucial in reaching this milestone. Together, we look forward to driving further innovation and progress.



### SUBCOMMITTEE UPDATE

Another development has been made in subcommittees. We have dissolved two subcommittees and merged them with existing ones to streamline our efforts. The Chronic Myeloproliferative Disorders Subcommittee is now merged with the AML Subcommittee, forming the "AML and Chronic Myeloproliferative Disorders Subcommittee," chaired by Smita Kayal. Additionally, the Rare Tumours Subcommittee is merged with the GCT Subcommittee, resulting in the "GCT and Rare Tumours Subcommittee," chaired by Sonali Mohapatra. These changes aim to enhance our focus and improve our collaborative impact in these critical areas.

### INPHOG STAFF

Today, our company employs seventeen members in total, including one research manager, one grant manager, one communication manager, 13 clinical research coordinators, and one HR professional.











CRC Name	Centre Name	Designation
Akshita Yadav	King George Medical University, Lucknow	Clinical Research Coordinator
Dr. Leya George	JIPMER, Puducherry	Clinical Research Coordinator
Aditya Ravindra Gaikwad	BJ Wadia Hospital, Mumbai	Clinical Research Coordinator
Sarthak Sahu	TMC, Kolkata	Clinical Research Coordinator
Priya Saxena	Indraprastha APOLLO - New Delhi	Clinical Research Coordinator
Nichila Mary Philip	Cancer Institute, Adyar	Clinical Research Coordinator
Shikha Kumari	AIIMS Hospital, New Delhi	Clinical Research Coordinator
Keerthika Murugesan	Apollo Chennai	Clinical Research Coordinator
Nisha Kumari	Safdarjung Hospital	Clinical Research Coordinator
Khushi Jha	Rajiv Gandhi Cancer Institute, New Delhi	Clinical Research Coordinator
Aishwarya Siddhi	DMC Hospital, Ludhiana, Punjab	Clinical Research Coordinator
Anjana Joseph	MVR Cancer Research Institute, Kozhikode	Clinical Research Coordinator
Kenson Alex	St Johns Medical College Hospital	Clinical Research Coordinator

### **STAFF TRAINING**

We have also started our extensive weekly staff training program. Our training program is designed to enhance the skills and knowledge of our team across various key areas:

**General Training:** Covers foundational knowledge essential for all staff members.

**Admin Training:** Focuses on administrative procedures to ensure smooth and efficient operations.

**Research/Statistical Training:** Enhances data analysis skills, critical for our research projects.

**New Study Training:** Prepares staff for upcoming projects, ensuring we stay at the forefront of pediatric hematology oncology research.

These training sessions reflect our commitment to continuous improvement and excellence in all aspects of our work.











### **TECHNICAL ADVISORS**

We are delighted to announce the addition of two esteemed technical advisors to INPHOG: Dr. Meenakshi Devidas and Dr. Pooja Sharma.

With their extensive expertise and experience in the research field, their involvement as technical mentors will be invaluable to our group. INPHOG is dedicated to advancing research, education, and collaboration in pediatric hematology oncology across India. Their guidance and mentorship will greatly contribute to achieving our mission and goals.



Dr Devidas earned a PhD in Applied Statistics from the University of Memphis and spent the ensuing 32 years as a faculty member at UCLA, the University of Mississippi Medical Center, and the University of Florida. She brings more than 26 years of experience in the field of pediatric oncology. She is the Director of Global Analytics in the Department of Global Pediatric Medicine at St Iude Children's Research Hospital. She and her team provide biostatistical and analytical support for the various global initiatives/research projects in the department.

Dr. Meenakshi Devidas Professor and Director, Global Analytics Unit, Department of Global Pediatric Medicine, St Jude Children's Research Hospital.



Dr. Pooja Sharma, MD (Obs and Gynae), is a distinguished clinician and researcher with a multifaceted expertise spanning clinical research, bioethics, and patient advocacy. With a solid educational foundation including an MD from the Institute of Medical Sciences, BHU, Varanasi, Dr. Sharma has been instrumental in shaping healthcare initiatives across various domains. As the Founder and CEO of APAR Health Services, Dr. Sharma demonstrates visionary leadership, driving the organization's mission to build a comprehensive Clinical Research capacity-building program. Her role as a Technical Advisor for INPHOG underscores her commitment to advancing pediatric healthcare and research strategies.

Dr. Pooja Sharma Founder CEO, APAR Health Services Research Advisor INPHOG Chairperson











Subcommittee	Provisional (7)	Full Registration (5)	Recruitment	Recruitment
ALL	Registration (7)	INPHOG-ALL-24-03	Ongoing (8) InPOG-ALL-19-02	Complete (21) InPOG-ALL-15-01
AML		INFIIOG-ALL-24-03	INPHOG-AML-23-02	INPOG-AML-16-01
Ch Myelop			INFIIOG-AML-25-02	InPOG-CML-16-01
HL		INPHOG-HL-24-04	InPOG-HL-19-03	InPOG-CML-16-01 InPOG-HL-15-01
HL		INPHOG-HL-24-04	INPOG-HL-19-03	InPOG-HL-17-02
NHL	INPHOG-NHL-PROV-01 INPHOG -NHL-PROV-02			InPOG-NHL-16-01
Histiocytosis	INPHOG-HIST-PROV-01			InPOG-HIST-17-01 InPOG-HIST-19-03
CNS	INPHOG-CNS-PROV-01			
Neuroblastoma		InPOG-NB-23-02		InPOG-NB-18-01
Retinoblastoma				InPOG-RB-19-01
Renal				InPOG-WT-18-02
Liver				
Osteosarcoma			INPHOG-OST-23-01	
PNET				InPOG-PNET-16-01 InPOG-PNET-19-02
STS				
Germ Cell Tum			INPHOG-GCT-22-01	
Rare, Epithelial				InPOG-RARE-17-02 InPOG-RARE-17-01
HSCT	InPOG-SCT-20-02			
Access to Care				InPOG-ACC-16-01 InPOG-ACC-16-03 InPOG-ACC-16-02 InPOG-ACC-20-04
Supportive Care		INPHOG-SUPP-23-04	INPHOG-SUPP-22-03	
Epidemiology		INPHOG-EPI-24-04	InPHOG-EPI-22-03	InPOG-EPI-20-02
Late Effects			InPOG-LE-16-01	
Palliative Care				InPOG-PALL-18-01
<b>Cancer Genetics</b>				
Hbpathy/RBC	INPHOG-RBC-22-01			
Plat & Coag				
BM Failure	INPHOG-BMF-PROV-01			











## INPHOG Studies - Recruitment Complete (21)

#### InPOG-HL-15-01

A collaborative study for newly diagnosed childhood Hodgkin's lymphoma patients in India

Principal Investigator Registered with INPHOG **CTRI Registration Patients recruited Recruitment Closed** Centers study open in

Prof Jagdish Chandra **June 2015** CTRI/2016/03/010916 410

February 2018 27 centers

### **Publications**

- Arora RS, Mahajan A, Dinand V, Kalra M, Jain S, Taluja A, Mandal P, Chandra J. InPOG-HL-15-01 - Challenges and Lessons Learnt in Setting up the First Collaborative Multicentre Prospective Clinical Trial in Childhood Cancer in India. Pediatric Hematology Oncology J 2020. Oct 1;5(4):166-70.
- Mahajan A, Singh M, Bakhshi S, Jain S, Seth R, Verma N, Kumar A, Radhakrishnan V, Mandal P, Kapoor G, Arora RS, Dinand V, Kalra M, Sharma A, Phulkar S, Arora A, Chandra J. Treating Early-Stage Hodgkin Lymphoma in resource-limited settings: InPOG-HL-15-01 Experience. Pediatric Blood & Cancer. 2021 Jul 22: e29219.
- Jain S, Bakhshi S, Seth R, Verma N, Singh M, Mahajan A, Radhakrishnan V, Mandal P, Arora RS, DinandV, Kalra M, Sharma A, Chandra J. Risk-based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced Hodgkin lymphoma treated with ABVD chemotherapy: A report from the Indian Pediatric Oncology Group study InPOG-HL-15-01. Leuk Lymphoma 2021 Dec 9:1-8
- Mahajan A, Bakhshi S, Singh M, Seth R, Verma N, Jain S, Radhakrishnan V, Mandal P, Arora RS, DinandV, Kalra M, Kapoor G, Sajid M, Kumar R, Mallick S, Taluja A, Chandra J. Empirical antitubercular treatment for lymphadenopathy: Are we missing lymphoma? Indian J Pediatr. 2022 Jun 23.
- Mahajan A, Bakhshi S, Seth R, Verma N, Mandal P, Singh M, Jain S, Radhakrishnan V, Kanvinde S, Arora RS, Dinand V, Kalra M, Taluja A, Mallick S, Kumar R, Chandra J. Hodgkin lymphoma in childrenunder 5 years: Do they behave differently? I Pediatr Hematol Oncol. 2022 May 1;44(4):186-190.
- Kalra M, Bakshi S, Singh M, Seth R, Verma N, Jain S, Radhakrishnan V, Mandal P, Mahajan A, Arora RS, Dinand V, Kapoor G, Sajid M, Kumar R, Taluja A, Mallick S, Chandral. Response assessment with Positron Emission Tomography-Computed tomography as compared with contrast-enhanced computed tomography in Childhood Hodgkin Lymphoma can reduce the need for radiotherapy in low- and middle-income countries. Pediatr Blood cancer 2022; e 30091.
- Banwait DK, Arora PR, Mahajan A, Dinand V, Jain S, Kalra M, Chandra J, Arora RS. Barriers to Accessing Fertility Preservation in Adolescents with Hodgkin Lymphoma in India. Pediatr Hematol Oncol. 2023 Jun 2:1-6.











### **InPOG NHL-16-01**

### A Retrospective Multi-Centric Study of Contemporary Epidemiology & Outcome of Childhood B-NHL in India

**Principal Investigator** Dr Amita Trehan Registered with INPHOG October 2016

**CTRI Registration** No Patients recruited 323

Recruitment Closed April 2018 09 centers Centers study open in

### **Publications**

Rahiman EA, Bakhshi S, Deepam Pushpam, Ramamoorthy J, Das A, Ghara N, Kalra M, Kapoor G, Meena JP, Siddaigarhi S, Thulkar S, Sharma MC, Srinivasan R, Trehan A. Outcome and prognosticfactors in childhood B non-Hodgkin lymphoma from India: Report by the Indian Pediatric Oncology Group (InPOG-NHL-16-01 study). Pediatr Hematol Oncol. 2022 Jan 3:1-15.

### InPOG-ACC-16-01

Multi-site Prospective Study to Determine Household Out-of-Pocket Expenditure Incurredby Families of Children Newly Diagnosed with Cancer in India (HOPE Study)

> Principal Investigator Dr Ramandeep Singh Arora

**Registered with INPHOG** August 2016

**CTRI** Registration CTRI/2016/11/007492

Patients recruited

**Recruitment Closed** November 2017

Centers study open in 15 centers

### InPOG-ACC-16-03

**Exploring Barriers and Enablers to Accessing Care for Childhood Cancers in India: A Multicenter Qualitative Study** 

**Principal Investigator** Dr Ramandeep Singh Arora

**Registered with INPHOG** May 2017

**CTRI Registration** No

**Patients recruited** 34 patients + 27 healthcare

**Recruitment Closed** January 2018 7 centers Centers study open in

### **Publications**

- Faruqui N, Joshi R, Martiniuk A, Lowe J, Arora R, Anis H, Kalra M, Bakhshi S, Mishra A, Santa A, Sinha S, Siddaiahgari S, Seth R, Bernays S. A health care labyrinth: perspectives of caregivers on the journeyto accessing timely cancer diagnosis and treatment for children in India. BMC Public Health. 2019 Dec2;19(1):1613.
- Faruqui N, Bernays S, Martiniuk A, Abimbola S, Arora R, Lowe J, Denburg A, Joshi R, Access to care forchildhood cancers in India: perspectives of health care providers and the implications for Universal Health Coverage. BMC Public Health 2020 Dec; 20(1):1-1.











### InPOG-PNET-16-01

Evaluation of clinicopathological characteristics, prognostic factors, and treatment outcomes in patients with PNET of Kidney: An InPOG study

Principal Investigator Dr Bivas Biswas Registered with INPHOG Iune 2016 **CTRI Registration** No

Patients recruited 40

**Recruitment Closed** August 2018 Centers study open in 2 centers

### InPOG-CML-16-01

Study of treatment and outcome of chronic myeloid leukemia in children and adolescents in India

**Principal Investigator** Prof Deepak Bansal

Registered with INPHOG Feb 2018

**CTRI Registration** No **Patients recruited** 171

January 2019 **Recruitment Closed** 9 centers Centers study open in

### **Publications**

Totadri, S., Mahajan, A., Gupta, V., Das, A., Meena, J.P., Singh, M., Mohammed, S., Aggarwal, P., Tuladhar, S., Seth, R., Naseem, S., Varma, N., Trehan, A. and Bansal, D. (2019), PS1178 TREATMENT AND OUTCOME OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS: THE INDIAN PEDIATRIC ONCOLOGY GROUP-CML-16-01 MULTICENTRIC **STUDY** 

### InPOG-AML-16-01

Randomized Phase III Study Comparing DA (3+7) Versus ADE as Induction Chemotherapy in Children with Acute Myeloid Leukemia

**Principal Investigator** Dr Venkatraman Radhakrishnan

Registered with INPHOG **April 2016** 

**CTRI Registration** CTRI/2014/11/005202

**Patients recruited** 150 **Recruitment Closed** Nov 2019 Centers study open in 5 centers

#### **Publications**

Radhakrishnan V, Bakhshi S, Kayal S, Thampy C, Batra A, Shenoy PK, Kumar H, Rajaraman S, Chaudhary S, Bisht R, Dubashi B, Ganesan TS. Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial. Blood Cancer J. 2022 Sep 6;12(9):131. doi: 10.1038/s41408-022-00726-1. Erratum in: Blood Cancer J. 2022 Sep 27;12(9):139. PMID: 36068213; PMCID: PMC9444698











### InPOG-HIST-17-01

Indian Hemophagocytic Lymphohistiocytosis Registry (I-HLH): Establishment of anationwide prospective web-based registry for patients diagnosed with HLH

> Principal Investigator Dr Mukesh Desai

Registered with INPHOG **July 2017 CTRI Registration** Not done Patients recruited 20

**Recruitment Closed** Feb 2021 Centers study open in 8 centers

### InPOG-ACC-16-02

Accessing Childhood CancEr ServiceS in INDIA (ACCESS INDIA)

**Principal Investigator** Dr Ramandeep Singh Arora

Registered with INPHOG Sep 2018 **CTRI Registration** Not done **Patients recruited** 2850 **Recruitment Closed** Feb 2021 Centers study open in 71 centers

### InPOG-ACC-20-04

The Impact of COVID-19 Pandemic on the care of children with cancer in India

**Principal Investigator** Dr Ramandeep Arora

Registered with INPHOG May 2020

**CTRI** Registration CTRI/2020/05/025219

Patients recruited 1146 **Recruitment Closed** Feb 2021 Centers study open in 30 centers

### **Publications**

Sharma J, Mahajan A, Bakhshi S, Patil V, Verma N, Radhakrishnan V, Singh A, Kayal S, Seth R, PushpamD, Arora RS. The impact of COVID-19 pandemic on access to treatment for children with cancer in India and treating center practices. Cancer. 2022 Feb 1;128(3),579-86.

### InPOG-ALL-15-01

An Indian Childhood Collaborative Leukemia Group multicentre national standardizationstudy for newly diagnosed acute lymphoblastic leukemia

**Principal Investigator** Prof Vaskar Saha

Registered with INPHOG July 2015

**CTRI Registration** CTRI/2015/12/006434

Patients recruited 2516 **Recruitment Closed** Aug 2022 5 centers Centers study open in











### **Publications**

Das N, Banavali S, Bakhshi S, Trehan A, Radhakrishnan V, Seth R, Arora B, Narula G, Sinha S, Roy P, Gogoi MP, Chatterjee S, Abraham B, Das P, Saha V, Krishnan S. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomized, multicentre, open label, controlled therapeutic trialfor newly diagnosed childhood acute lymphoblastic leukemia in India. Tri<mark>als.</mark> 2022 Jan 31;23(1):102.

### InPOG-HL-17-02

### Prospective Collaborative Study for Relapsed/Refractory Hodgkin Lymphoma

Principal Investigator Dr Amita Mahajan

Registered with INPHOG May 2018

**CTRI Registration** Ref/2019/03/024719

Patients recruited

SEP 2023 **Recruitment Closed** Centers study open in 13 centers

### InPOG-NB-18-01

### India Neuroblastoma Registration and Biology Study

**Principal Investigator** Dr Vikramjit Kanwar

Nov 2018 Registered with INPHOG

CTRI/2020/01/023088 **CTRI Registration** 

Patients recruited

**Recruitment Closed SEP 2023** Centers study open in 13 centers

### InPOG-EPI-20-02

### **Indian COVID-19 Childhood Cancer Registry**

**Principal Investigator** Dr. Revathi Raj Registered with INPHOG May 2020

**CTRI Registration** CTRI/2020/05/025221

Patients recruited

**IUL 2023** Recruitment Closed Centers study open in 37 centers

### **Publications**

Raj R, Uppuluri R, Parambil B, Dhariwal N, Totadri S, Mathew LG, Radhakrishnan V, Charan A, Yadav SP, Mahajan A, Mudaliar S. Outcomes of COVID-19 in children with cancer-Report from the Indian Pediatric Oncology Group (InPOG)COVID-19 registry in India. Pediatric Hematology Oncology Journal. 2022 Jun 1;7(2):34-7.











#### InPOG-PALL-18-01

# Patterns of End-Of-Life Care in Children with Cancer in India – A Multicentre RetrospectiveStudy

Principal Investigator Dr Gayatri Palat

**Registered with INPHOG** Sep 2020

CTRI Registration CTRI/2020/12/029960

Patients recruited384Recruitment ClosedJUL 2023Centers study open in17 centers

#### InPOG-WT-18-02

Pattern of care and survival of renal tumors in children in India - Multi-center study

Principal Investigator Dr. Sirisharani Siddaiahgari

**Registered with INPHOG** Apr 2020

CTRI Registration CTRI/2021/01/030770

Patients recruited443Recruitment ClosedJUL 2023Centers study open in17 centers

### InPOG-HIST-19-03

Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed / Refractory Langerhans Cell Histiocytosis (LENDEX-LCH study)

Principal Investigator Dr Ramya Uppuluri

**Registered with INPHOG** Aug 2019

CTRI Registration CTRI/2020/07/026937

Patients recruited 15

**Recruitment Closed** DEC 2023

Centers study open in 07

### InPOG-RARE-17-02

Indian Childhood Advanced Nasopharyngeal Carcinoma Study (ICANaPS)
A multicenter, prospective, pilot study on the use of platinum-based chemotherapy for pediatric nasopharyngeal carcinoma and exploration of the role of plasma Epstein-Barr virus (EBV)- DNA PCR titers in predicting relapse

Principal Investigator Dr Reghu
Registered with INPHOG October 2018

**CTRI Registration** 

Recruitment commenced Yes
Currently, patients recruited 2
Target patient recruitment 50
Anticipated duration of recruitment 5 years
Centers study open in 1











### InPOG-RARE-17-01

Clinical Course, Pathological Spectrum and Outcomes in Paediatric Rare **Tumours in India: A Multicentric Observational Study** 

**Principal Investigator** Dr Maya Prasad

Registered with INPHOG July 2017

CTRI Registration CTRI/2019/02/017851

Recruitment commenced Yes Currently, patients recruited 384 **Target patient recruitment** 250 Anticipated duration of recruitment 5 years Centers study open in 10 centers

### InPOG-PNET-19-02

Evaluation of clinic-pathological characteristics, prognostic factors, and treatment outcomes inpatients with ESFT in children and young adults.

**Principal Investigator** Dr Sandeep Jain Registered with INPHOG May 2021 **CTRI Registration** Applied for

Recruitment commenced Yes **Currently**, patients recruited 1600 Target patient recruitment 1000

Anticipated duration of recruitment Not applicable - Retrospective

Centers study open in

### InPOG-RB-19-01

A Prospective Collaborative Study for Newly Diagnosed Patients with Retinoblastoma

**Principal Investigator** Dr Santosh Honavar

Registered with INPHOG Sep 2019

**CTRI Registration** CTRI/2020/09/027846

**Recruitment commenced** Yes 1120 **Currently, patients recruited** Target patient recruitment 1066 Anticipated duration of recruitment 3 years 20 Centers study open in











# INPHOG Studies - Recruitment Ongoing (08)

#### InPOG-LE-16-01

The Indian Childhood Cancer Survivorship Study (C2S study): After treatment completionregistry of childhood cancers - Phase 1

**Principal Investigator** Dr Rachna Seth Registered with INPHOG May 2016 **CTRI Registration** Not done Recruitment commenced June 2016 Currently, patients recruited 3957

**Target patient recruitment** At least 500 (desirable 1000) Anticipated duration of recruitment 5 years (Project extended till 2025)

Centers study open in 21 centers

- All India Institute of Medical Sciences, New Delhi
- AIIMS, Jodhpur
- Apollo Hospital, Chennai
- Banaras Hindu University, Varanasi
- Cancer Institute, Adyar Chennai
- Indraprastha Apollo Hospital, New Delhi
- Kalawati Saran Children's Hospital, New Delhi
- Kidwai Memorial Institute, Bangalore
- King George's Medical University, Lucknow
- Kasturba Medical College, Manipur New
- Max Super Specialty Hospital, Patparganj, New Delhi
- Max Super Specialty Hospital, Saket, New Delhi
- MVR Cancer Centre and Research Institute
- Post Graduate Institute of Child Health, Noida
- Rainbow Children's Hospital, Hyderabad
- Rajiv Gandhi Cancer Institute, New Delhi
- Regional Cancer Centre, Thiruvananthapuram
- Safdarjung Hospital, New Delhi
- SION Hospital, Mumbai
- Tata Medical Centre, Kolkata
- Tata Memorial Hospital, Mumbai

### InPOG-ALL-19-02

Registry study for relapsed childhood acute lymphoblastic leukemia using protocol ALL-R1.

Principal Investigator Vaskar Saha Registered with INPHOG Jun 2019

CTRI/2019/10/021758 **CTRI Registration** 

Recruitment commenced Yes Currently, patients recruited 67











Target patient recruitment 220 **Anticipated duration of recruitment** 5 years Centers study open in

Tata Medical Centre, Kolkata

### InPOG-HL-19-03

Response-adapted management of Childhood Classical Hodgkin Lymphoma (cHL) and Early Response Assessment by Positron Emission and Computerized Tomography (PET-CT) to allow Omission of Radiotherapy in Indian Children Treated with a Standard of Care IntensifiedChemotherapy Regimen.

Dr Gaurav Narula **Principal Investigator** 

Registered with INPHOG Feb 2020

**CTRI Registration** CTRI/2020/08/027495

**Recruitment commenced** Yes **Currently**, patients recruited 236 **Target patient recruitment** 700 Anticipated duration of recruitment 5 years Centers study open in 10

Apollo Cancer Centre, Chennai

- Bai Jerabai Wadia Hospital, Mumbai
- Cancer Institute (W.I.A) Adyar, Chennai
- Homi Bhabha Cancer Hospital, Varanasi
- Indraprastha Apollo Hospital, Delhi
- Kasturba Medical College, Manipal
- Max Super Specialty Hospital, Saket, New Delhi
- Malabar Cancer Center, Kerala New
- Rajiv Gandhi Cancer Institute & Research center, Delhi
- Tata Memorial Hospital, Mumbai

### **INPHOG-SUPP-22-03**

Anti-Emetic Prophylaxis for Chemotherapy-Induced Vomiting Without Dexamethasone for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Open-Label, Multi-Center, Non-Inferiority, **Phase III Randomized Controlled Trial** 

> **Principal Investigator** Dr Venkatraman Radhakrishnan

Registered with INPHOG **June 2022** 

**CTRI Registration** CTRI/2022/08/045009

Recruitment commenced No **Currently**, patients recruited 146 Target patient recruitment 300 Anticipated duration of recruitment 3 years Centers study open in











- AIIMS, New Delhi
- Apollo Hospital, New Delhi
- Cancer Institute, Chennai
- **IIPMER**, Puducherry
- KKCTH, Chennai
- Max Hospital, New Delhi

### INPHOG-GCT-22-01

Integrated Clinico-pathological and treatment outcome analysis of extra-cranial malignantgerm cell tumors in children and adolescents in India.

> **Principal Investigator** Dr Sonali Mohapatra

Registered with INPHOG March 2023 **CTRI Registration Applied For** 

**Recruitment commenced** Yes **Currently**, patients recruited 380 Target patient recruitment 400-500 **Anticipated duration of recruitment** 18 Months

Centers study open in 17

- AIIMS Bhuvneshwar
- AIIMS, Bhopal New
- AIIMS, New Delhi New
- Apollo, Chennai New
- BHU, Varanasi New
- Cancer Institute (WIA), Adyar New
- Dayanand Medical College & Hospital, Ludhiana
- Indraprastha Apollo Hospitals, New Delhi
- Kasturba Medical College, Manipal New
- KGMU, Lucknow New
- MVR Cancer Centre, Kozhikode
- Rajiv Gandhi Cancer Institute & Research Center, Delhi New
- Rainbow Children's Hospital, Hyderabad
- SKIMs, Jammu and Kashmir
- St Johns Medical College Hospital, Bangalore New
- SGRH, New Delhi New
- Tata Medical Centre, Kolkata New











### INPHOG-EPI-22-03

Establishing the first dedicated Population-Based Childhood Cancer Registry (PBCCR) and network of Hospital-Based Childhood Cancer Registries (HBCCRs) in India.

> Principal Investigator Dr Venkatraman Radhakrishnan

Registered with INPHOG Sep 2022

**CTRI Registration** CTRI/2022/06/043526

Recruitment commenced Sep 2022 439 **Currently**, patients recruited Target patient recruitment 1000

Anticipated duration of recruitment Continuous

Centers study open in 18

Apollo Specialty Hospital, Chennai

- Cancer Institute (WIA), Adyar
- Dr. Rela Hospital, Chennai
- Dr. Mehta's Hospital, Chennai
- Global Hospital, Chennai
- ICH Government Hospital. Chennai
- Kauvary Hospital, Chennai
- Kanji Kamakodi Child Trust Hospital, Chennai
- Kumaran Hospital, Chennai NEW
- Rajiv Gandhi Government Hospital, Chennai
- Rainbow Children's Hospital
- Roya Pettah Government Hospital, Chennai
- Sankara Nethralaya Eye Hospital, Chennai
- SIMS Hospital Chennai
- Sri Ramachandra Medical Centre, Chennai
- Standely Government Hospital, Chennai
- Tamil Nadu Multispecialty Hospital, Chennai
- VS Hospital Chennai

### INPHOG-AML-23-02

### Indian Childhood Acute Promyelocytic Leukemia Study (I-CHAMPs)

**Principal Investigator** Dr Smita Kayal Registered with INPHOG March 2023

**CTRI Registration** CTRI/2024/04/065353

Recruitment commenced March 2024

Currently, patients recruited 25 (Retrospective) **Target patient recruitment** 100-200 Annually

Anticipated duration of recruitment Retrospective Registry (1 year)/

Prospective Registry (5 years)

Centers study open in 9











- AIIMS, New Delhi
- Apollo Hospital, New Delhi
- ABVIMS & Dr RML Hospital, New Delhi **NEW**
- Dayanand Medical College & Hospital, Ludhiana
- Dr. Bhubaneswar Borooah Cancer Institute **NEW**
- JIPMER, Puducherry
- KGMU, Lucknow
- MVR Cancer Centre and Research Institute
- Postgraduate Institute of Child Health, Noida **NEW**

### IMSOS OS 01/INPHOG -OST-23-01

Evaluation of Clinico-pathological characteristics, prognostic factors, and treatment outcomes in patients with osteosarcoma in children and adults treated in India"

**Principal Investigator** Dr Akshay Tiwari

**Registered with INPHOG** OCT 2023

**CTRI Registration** CTRI/2023/05/053100

**Recruitment commenced** No **Currently**, patients recruited NA

**Target patient recruitment** Not specified Anticipated duration of recruitment Not specified

Centers study open in No











# INPHOG Studies Granted Full Registration (5)

### InPOG-HL-24-01

### Immunotherapeutic strategies in children and adolescents with Hodgkin lymphoma

**Principal Investigator** Dr Amita Mahajan

Registered with INPHOG Mar 2024

**CTRI Registration** 

**Recruitment commenced** No Currently, patients recruited NA

**Target patient recruitment** Not specified **Anticipated duration of recruitment** 6 years Centers study open in No

### **InPOG-NB-23-02**

### **Indian Non-high Risk Neuroblastoma Study**

**Principal Investigator** Dr Yamini Krishnan

Registered with INPHOG Apr 2024 **CTRI Registration Applied For** 

**Recruitment commenced** No Currently, patients recruited NA **Target patient recruitment** 150 3 Years **Anticipated duration of recruitment** Centers study open in No

#### INPHOG-SUPP-23-04

Drug-induced Diabetes Mellitus management in children with Acute Leukemia (ALL) - A Phase-2 Open-Label Randomized Control Trial (RCT) comparing two treatment arms (Insulin alone Vs Insulin + Metformin)

> **Principal Investigator** Dr. Kalasekhar V.S

Registered with INPHOG May 2024 **CTRI Registration Applied For** 

**Recruitment commenced** No Currently, patients recruited NA

**Target patient recruitment** Not specified Anticipated duration of recruitment Not specified

Centers study open in No











### INPHOG-EPI-24-04

### ESTABLISHING THE INPHOG NETWORK OF HOSPITAL-BASED CHILDHOOD CANCER **REGISTRIES (HBCCRs) IN INDIA**

**Principal Investigator** Dr Venkatraman Radhakrishnan

Apr 2024 **Registered with INPHOG** 

**CTRI Registration** CTRI/2024/05/067345

**Recruitment commenced** No **Currently, patients recruited** NA

**Target patient recruitment** Not specified Anticipated duration of recruitment 5 Years Centers study open in 50

### **INPHOG-ALL-24-03**

Improving Survival in Childhood Acute Lymphoblastic Leukemia in India (ISCALL): **ICiCLE Implementation Study."** 

> **Principal Investigator** Dr Venkatraman Radhakrishnan

**Registered with INPHOG** Apr 2024

CTRI/2023/12/060828 **CTRI Registration** 

**Recruitment commenced** May 2024

**Currently, patients recruited** No

**Target patient recruitment** Not Specified Anticipated duration of recruitment 4 Years Centers study open in 26











### INPHOG Studies Granted Provisional Registration (7)

**InPOG-SCT-20-02 (P)** A multicenter collaborative study for evaluating the outcome in children with high-risk neuroblastoma undergoing autologous stem cell transplantation (NBL-ASCT). PI - Venkateswaran V S

INPHOG-RBC-22-01 (P) A Cross-sectional study of children receiving regular red cell transfusions for primary non-malignant hematological conditions excluding thalassemia and sickle cell anemia- Assessment of disease burden and clinical profile. PI - Stalin Ramprakash

INPHOG-CNS-PROV-01 Multicentric Indian Pediatric Low-Grade Glioma Registry (IPLOGG): Epidemiology, Treatment Patterns, and Outcomes PI - Vikramjit Kanwar/Rakesh Jalali

**INPHOG-HIST-PROV-01** A multicentre, retrospective study demography, presentation, treatment, and outcome of Langerhans cell histiocytosis in India PI - Ramya Uppuluri

INPHOG-NHL-PROV-01 A prospective multi-centric study on practice, clinical outcomes, and toxicities in children with mature B-cell non-Hodgkin lymphoma treated with a Rituximab-based chemotherapy regimen PI - Dr. Nirmalya

INPHOG-BMF-PROV-01 Frequency, Natural History, and Improved Diagnosis of Inherited Bone Marrow Failure Syndromes (IBMFS) in India: An Ambispective Multi-Centric Study PI - Dr Ruchira Mishra

INPHOG-NHL-PROV-02 Safety and Efficacy of Reduced Dose Chemotherapy in Children and Adolescents with high-grade Mature B Non-Hodgkin Lymphoma - A Prospective Multicenter Phase II Single Arm Study (RED X – B NHL Study)" PI - Prasanth Srinivasan







